| Title | Author | Year | SCOPUS | PUBMED | ISI | TCI | |
|---|---|---|---|---|---|---|---|
| 1. | Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1-related anti-apoptotic proteins | Paksiree Saranaruk Ryusho Kariya Gunya Sittithumcharee Parichart Boueroy Thidarut Boonmars Kanlayanee Sawanyawisuth Chaisiri Wongkham Sopit Wongkham Seiji Okada Kulthida Vaeteewoottacharn |
2020 | ||||
| 2. | Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1‑related anti‑apoptotic proteins. | Boonmars, T. Sawanyawisuth, K. Wongkham, C. Wongkham, S. Okada, S. Vaeteewoottacharn, K. |
2020 | ||||
| 3. | The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling. | Marutpong Detarya Kanlayanee Sawanyawisuth Chaiwat Aphivatanasiri Sriwipa Chuangchaiya Paksiree Saranaruk Lukkana Sukprasert Atit Silsirivanit Norie Araki Sopit Wongkham Chaisiri Wongkham |
2020 | ||||
| 4. | Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma | Seubwai, W. Cha'on, U. Wongkham, S. |
2021 | ||||
| 5. | Five-(Tetradecyloxy)-2-furoic acid alleviates cholangiocarcinoma growth by inhibition of cell-cycle progression and induction of apoptosis | Boonnate, P Kariya, R Saranaruk, P Cha'on, U Sawanyawisuth, K Jitrapakdee, S Okada, S Vaeteewoottacharn, K |
2021 | ||||
| 6. | Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor. | Obchoei, S. Detarya, M. Boonnate, P. Saranaruk, P. Vaeteewoottacharn, K. Mahalapbutr, P. Wongkham, S. |
2022 | ||||
| 7. | Dense GM-CSFRα-expressing immune infiltration is allied with longer survival of intrahepatic cholangiocarcinoma patients | Saranaruk, P. Waraasawapati, S. Chamgramol, Y. Sawanyawisuth, K. Paungpan, N. Somphud, N. Wongkham, C. Okada, S. Wongkham, S. Vaeteewoottacharn, K. |
2023 | ||||
| 8. | Dense GM-CSFR-expressing immune infiltration is allied with longer survival of intrahepatic cholangiocarcinoma patients. | Saranaruk, P Waraasawapati, S Chamgramol, Y Sawanyawisuth, K Paungpan, N Somphud, N Wongkham, C Okada, S Wongkham, S Vaeteewoottacharn, K |
2023 | Count | 6 | 6 | 3 | 0 |
| Title | Authors | Year | Publication name | Cited count | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | รวม | ||||||
| 1. | Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1‑related anti‑apoptotic proteins | Boonmars, T. Sawanyawisuth, K. Wongkham, C. Wongkham, S. Okada, S. Vaeteewoottacharn, K. |
2020 |
International Journal of Molecular Medicine 4 (45), pp. 1005-1016 |
||||||||
| 2. | The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling | Sawanyawisuth, K. Silsirivanit, A. Wongkham, S. Wongkham, C. |
2020 |
Glycobiology 5 (30), pp. 312-324 |
||||||||
| 3. | Aberrant GLUT1 expression is associated with carcinogenesis and progression of liver fluke-associated cholangiocarcinoma | Seubwai, W. Cha'on, U. Wongkham, S. |
2021 |
In Vivo 1 (35), pp. 267-274 |
||||||||
| 4. | Five-(Tetradecyloxy)-2-furoic acid alleviates cholangiocarcinoma growth by inhibition of cell-cycle progression and induction of apoptosis | Boonnate, P. Saranaruk, P. Cha'on, U. Sawanyawisuth, K. Okada, S. Vaeteewoottacharn, K. |
2021 |
Anticancer Research 7 (41), pp. 3389-3400 |
||||||||
| 5. | Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor | Obchoei, S. Detarya, M. Boonnate, P. Saranaruk, P. Vaeteewoottacharn, K. Mahalapbutr, P. Wongkham, S. |
2022 |
Asian Pacific Journal of Cancer Prevention 10 (23), pp. 3379-3386 |
||||||||
| 6. | Dense GM-CSFRα-expressing immune infiltration is allied with longer survival of intrahepatic cholangiocarcinoma patients | Saranaruk, P. Waraasawapati, S. Chamgramol, Y. Sawanyawisuth, K. Paungpan, N. Somphud, N. Wongkham, C. Okada, S. Wongkham, S. Vaeteewoottacharn, K. |
2023 |
PeerJ (11), pp. |
||||||||
| Title | Authors | Year | Journal title | ||
|---|---|---|---|---|---|
| 1. | The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling. | Detarya, M Sawanyawisuth, K Aphivatanasiri, C Chuangchaiya, S Saranaruk, P Sukprasert, L Silsirivanit, A Araki, N Wongkham, S Wongkham, C |
2020 |
Glycobiology 5 (30), pp. 312-324 |
|
| 2. | Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1‑related anti‑apoptotic proteins. | Saranaruk, P Kariya, R Sittithumcharee, G Boueroy, P Boonmars, T Sawanyawisuth, K Wongkham, C Wongkham, S Okada, S Vaeteewoottacharn, K |
2020 |
International journal of molecular medicine 4 (45), pp. 1005-1016 |
|
| 3. | Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma. | Thamrongwaranggoon, U Sangkhamanon, S Seubwai, W Saranaruk, P Cha'on, U Wongkham, S |
2021 |
In vivo (Athens, Greece) 1 (35), pp. 267-274 |
|
| 4. | Five-(Tetradecyloxy)-2-furoic Acid Alleviates Cholangiocarcinoma Growth by Inhibition of Cell-cycle Progression and Induction of Apoptosis. | Boonnate, P Kariya, R Saranaruk, P Cha'on, U Sawanyawisuth, K Jitrapakdee, S Okada, S Vaeteewoottacharn, K |
2021 |
Anticancer research 7 (41), pp. 3389-3400 |
|
| 5. | Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor. | Obchoei, S Detarya, M Boonnate, P Saranaruk, P Vaeteewoottacharn, K Mahalapbutr, P Okada, S Wongkham, S |
2022 |
Asian Pacific journal of cancer prevention : APJCP 10 (23), pp. 3379-3386 |
|
| 6. | Dense GM-CSFR-expressing immune infiltration is allied with longer survival of intrahepatic cholangiocarcinoma patients. | Saranaruk, P Waraasawapati, S Chamgramol, Y Sawanyawisuth, K Paungpan, N Somphud, N Wongkham, C Okada, S Wongkham, S Vaeteewoottacharn, K |
2023 |
PeerJ (11), pp. e14883 |
| Title | Authors | Year | Journal title | Cited count | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | รวม | ||||||
| 1. | Chromomycin A3 suppresses cholangiocarcinoma growth by induction of S phase cell cycle arrest and suppression of Sp1-related anti-apoptotic proteins | Paksiree Saranaruk Ryusho Kariya Gunya Sittithumcharee Parichart Boueroy Thidarut Boonmars Kanlayanee Sawanyawisuth Chaisiri Wongkham Sopit Wongkham Seiji Okada Kulthida Vaeteewoottacharn |
2020 |
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 4.0 (45.0), pp. 1005.0-1016.0 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 2. | The O-GalNAcylating enzyme GALNT5 mediates carcinogenesis and progression of cholangiocarcinoma via activation of AKT/ERK signaling | Marutpong Detarya Kanlayanee Sawanyawisuth Chaiwat Aphivatanasiri Sriwipa Chuangchaiya Paksiree Saranaruk Lukkana Sukprasert Atit Silsirivanit Norie Araki Sopit Wongkham Chaisiri Wongkham |
2020 |
GLYCOBIOLOGY 5.0 (30.0), pp. 312.0-324.0 |
11 | 0 | 0 | 0 | 0 | 0 | 11 | |
| 3. | Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma | Ubonrat Thamrongwaranggoon Sakkarn Sangkhamanon Wunchana Seubwai Paksiree Saranaruk U. B. O. N. CHA'ON Sopit Wongkham |
2021 |
IN VIVO 1.0 (35.0), pp. 267.0-274.0 |
1 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Title | Authors | Year | Journal title |
|---|
| ชื่อโครงการ | Authors | ประเภทโครงการ | ปีงบประมาณ | ทุนวิจับ |
|---|